Investigating the Economic Impacts of New Public Pharmaceutical Policies in Greece: Focusing on Price Reductions and Cost-Sharing Rates

Value in Health Regional Issues

Volumn 4, Issue , 2014, Pages 107-114

  Olga, Siskou Ch ^a   Daphne, Kaitelidou Ch ^a   Panagiota, Litsa S ^b   Georgia, Georgiadou S ^b   Helen, Alexopoulou A ^b   Panagiotis, Paterakis G ^b   Sotiria, Argyri P ^c   Lycourgos, Liaropoulos L ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b Oral Medicine Clinic National Organization for the Provision of Health Services (IKA)   (Greece)

^c General Secretariat of Social Security   (Greece)

Author keywords

Cost sharing levels; Pharmaceutical prices; Public pharmaceutical policies

Indexed keywords

AGENTS ACTING ON THE EYE; AGENTS ACTING ON THE PERIPHERAL NERVOUS AND NEUROMUSCULAR SYSTEMS; ANTACID AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT; DERMATOLOGICAL AGENT; HEMATOLOGIC AGENT; HORMONE; IMMUNOLOGIC AGENT; ORAL ANTIDIABETIC AGENT; RESPIRATORY TRACT AGENT; URINARY TRACT AGENT;

ARTICLE; CONTROLLED STUDY; COST CONTROL; COST SHARING LEVEL; DRUG COST; DRUG MARKETING; DRUG USE; ECONOMIC EVALUATION; GREECE; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEALTH CARE POLICY; HOUSEHOLD; HUMAN; NATIONAL ORGANIZATION FOR HEALTH CARE SERVICES PROVISION; PRESCRIPTION; PRICE REDUCTION; REIMBURSEMENT; SEASONAL VARIATION; SOCIAL SECURITY;

EID: 84907985353     PISSN: 22121099     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vhri.2014.07.003     Document Type: Article

References (15)

1. IMS Total unaudited and audited global pharmaceutical market, 2003-2010. Health Market Prognosis 2011.
2. Carone G., Schwierz C., Xavier A. Cost-Containment Policies in Public Pharmaceutical Spending in the EU 2012, Economic Papers 461, European Commission, Brussels, Belgium.
3. Tele P., Groot W. Cost-containment measures for pharmaceutical expenditure in the EU countries: a comparative analysis. Open Health Serv Policy J 2009, 2:71-83.
4. Greek System of Health Accounts. Athens, Greece: Center for Health Services Management and Evaluation, Nursing Department, National and Kapodistrian University of Athens, 2013.
5. OECD health data statistics. Available from: . 2013. [Accessed January 29, 2014]. http://stats.oecd.org/index.aspx?DataSetCode=HEALTH_STAT.
6. Siskou O, Kaitelidou D, Schneider M, et al. Analyzing pharmaceutical expenditure in Greece in a systematic way: unwinding Ariadne's clue. Presented at: ISPOR 15th Annual European Congress, November 3-7, 2012, Berlin, Germany.
7. Memorandum of Understanding between the European Commission and Hellenic Republic. Available from: . 2012. [Accessed January 27, 2014]. http://ec.europa.eu/economy_finance/eu_borrower/mou/2012-03-01-greece-mou_en.pdf.
8. Vandoros S., Stargardt T. Reforms in the Greek pharmaceutical market during the financial crisis. Health Policy 2013, 109:1-6.
9. Lurk J., Dejong D., Woods M., et al. Effects of changes in patient cost sharing and drug sample policies on prescription drug costs and utilization in a safety-net-provider setting. Am J Health Syst Pharm 2004, 61:267-272.
10. Mrazek M., Mossialos E. Regulating pharmaceutical prices in the European Union. Regulating Pharmaceuticals in Europe: Striving from Efficiency, Equity and Quality. European Observatory on Health Systems and Policies Series 2004, Open University Press, Berkshire, UK. E. Mossialos, M. Mrazek, T. Walley (Eds.).
11. Rietveld A.d., Haaijer-Ruskamp F. Policy options for cost-containment of pharmaceuticals. Drugs and Money-Prices Affordability and Cost Containment 2003, World Health Organization, Amsterdam, The Netherlands. M. Dukes, F. Haaijer-Ruskamp, C. Joncheere, A. Rietveld (Eds.).
12. Zafiropoulou M, Kaitelidou D, Siskou O, Economou Ch, Impacts of the crisis on access to healthcare services: country report on Greece. Available from:. 2014. [Accessed June 27, 2014]. http://www.eurofound.europa.eu/areas/health/healthcareservices.htm.
13. Economou C., Kaitelidou D., Kentikelenis A., et al. The Impact of Financial Crisis on the Health System and Health in Greece. Country Report for WHO. Amsterdam, The Netherlands: WHO Regional Office 2014.
14. Deloitte Centre for Health Solutions. Impact of Austerity on European Pharmaceutical Policy and Pricing-Staying Competitive in a Challenging Environment. Deloitte, London: Deloitte Centre for Health Solutions, 2013.
15. Torres I.V., Junoy J., Raya J. The impact of repeated cost containment policies on pharmaceutical expenditure: experience in Spain. Eur J Health Econ 2011, 12:563-573.